Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEPER
jRCTs061180022Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, bevacizumab, irinotecan, oxaliplatin, fluorouracil and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Deepness of Response. Started Sep 2015; status: completed.
02
Drugs
cetuximabbevacizumabirinotecanoxaliplatinfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs061180022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180022.